Summary
Biogen Inc. (BIIB) filed an 8-K on June 10, 2026, reporting the final voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. The meeting's primary outcomes included the election of ten directors to the Board and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, stockholders provided an advisory vote on executive compensation. Investors can view the detailed voting outcomes for each director nominee, which indicate overwhelming support for most candidates, with a few exceptions receiving notably fewer 'for' votes but still comfortably elected. The ratification of the auditor and the advisory vote on executive compensation also received significant stockholder approval, suggesting general confidence in the company's governance and financial oversight for the upcoming fiscal year.
Key Highlights
- 1Biogen Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026.
- 2Ten nominees were elected to Biogen's Board of Directors to serve until the 2027 annual meeting.
- 3All ten director nominees received a majority of the votes cast in their favor, with some nominees like Lloyd Minor and Menelas Pangalos receiving particularly high 'for' vote counts.
- 4PricewaterhouseCoopers LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 5The selection of PricewaterhouseCoopers LLP as auditor was overwhelmingly approved by stockholders.
- 6An advisory vote on executive compensation was approved by a significant majority of stockholders.
- 7The filing provides detailed vote counts for each director nominee, including 'for', 'against', 'abstentions', and 'broker non-votes'.